射干麻黄汤加减联合信必可治疗哮喘-慢性阻塞性肺疾病重叠综合征急性发作期临床研究

王淑敏; 马健; 金亚明

射干麻黄汤加减联合信必可治疗哮喘-慢性阻塞性肺疾病重叠综合征急性发作期临床研究

1.
南京中医药大学基础医学院，江苏南京 210023
2.
泰州市中医院呼吸科，江苏泰州 225300

计量
- 文章访问数: 1299
- HTML全文浏览量: 8
- PDF下载量: 1314
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-11
- 修回日期: 2017-06-20
- 刊出日期: 2017-09-10

Clinical Observation on Modified Sheganmahuang Tang Plus Symbicort in Treating the Acute Attack of Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome

1.
School of Basic Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China
2.
Respiratory Department of Taizhou Hospital of Chinese Medicine, Taizhou, 225300, China

摘要

摘要: 目的观察射干麻黄汤联合信必可治疗哮喘-慢性阻塞性肺疾病重叠综合征（ACOS）急性发作期的临床疗效。方法将42例痰湿阻肺证ACOS患者按随机数字法分为试验组（22例）和对照组（20例），在吸氧、止咳化痰、扩张支气管、抗感染等常规西药对症治疗基础上，对照组予信必可吸入，试验组予射干麻黄汤联合信必可治疗，疗程为4周，观察2组治疗效果。结果临床疗效上，试验组和对照组患者的总有效率为96.00%和65.00%，组间比较，P<0.05；第1秒用力呼气量占预计值百分比(FEV1%)、第1秒用力呼气量占用力肺活量百分比（FEV1/FVC）较对照组明显升高，P<0.05，CO弥散量（DLCO）试验组较对照组略升高，P>0.05；哮喘控制测试评分（CAT）为（16±2）较对照组(20±2)显著降低，慢性阻塞性肺疾病评分（ACT）为（24±3）较对照组(16±2)显著提升，P<0.05~0.01；2组皆无严重不良反应。结论射干麻黄汤联合信必可治疗ACOS急性发作期疗效满意，无严重不良反应，值得推广。
- 哮喘-慢性阻塞性肺疾病重叠综合征 /
- 射干麻黄汤 /
- 信必可
Abstract: OBJECTIVE To observe the clinical effect of modified Sheganmahuang Tang plus symbicort in treating the acute attack of asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS). METHODS Forty-two ACOS patients were divided into the experimental group (22 cases) and the control group (20 cases) according to the random number. On the basis of conventional western drug symptomatic treatment including oxygen inhalation， stopping cough and resolving phlegm， bronchus dilation， anti-infection， the control group was given symbicort inhalation， and the experimental group was given Sheganmahuang Tang plus symbicort. The treatment course was 4 weeks. the curative effects of both groups were observed. RESULTS In terms of clinical effect， the totally effective rates of the experimental group and the control group were 96.00% and 65.00%， respectively， and the difference between two groups was significant， P<0.05. The FEV1% and FEV1/FVC increased significantly compared with the control group， P<0.05. DLCO in the experimental group increased slightly higher than that in the control group， P>0.05; CAT score (16±2) decreased significantly compared with the control group (20±2); and the ACT score (24±3) increased significantly compared with the control group (16±2)， P<0.05. The reoccurrence rate in the experimental group decreased significantly compared with the control group， P<0.05~0.01. Both groups reported no severe adverse event. CONCLUSION Sheganmahuang Tang plus symbicort achieves satisfactory curative effect in the treatment of acute attack of ACOS with no severe adverse event， which is worthy of spreading.
- asthma-chronic obstructive pulmonary disease overlap syndrome /
- Sheganmahuang Tang /
- symbicort

HTML全文

参考文献(18)

[1]	金哲，王广发.慢性阻塞性肺疾病全球倡议（2014更新版）解读[J].中国医学前沿杂志（电子版)，2014，6(2):94-97.
[2]	JIN Z， WANG GF. The global initiative for chronic obstructive pulmonary disease (2014 update)[J]. J Chin Med Front (Electr Ver)， 2014， 6(2): 94-97.
[3]	何权瀛.2014年全球哮喘防治创议(GINA)简介[J].浙江医学，2014，36(19):1588-1600.
[4]	〖JP2〗HE QY. Introduction of global asthma prevention and prevention (GINA) in 2014[J]. Zhejiang Med， 2014，36(19):1588-1600.〖JP〗
[5]	姜慧娟.噻托溴铵粉联合布地奈德福莫特罗吸入治疗支气管哮喘-慢性阻塞性肺疾病重叠综合征的短期疗效观察[J].中国实用医药，2016，11(35)：93-95.
[6]	〖JP2〗JIANG HJ. Observation on short-term curative effect of bronchial asthma and chronic obstructive pulmonary disease overlap syndrome treated by tiotropium bromide powder combined with symbicort turbulaler inhalation[J]. Chin Pract Med， 2016， 11(35):93-95.〖JP〗
[7]	陈石，李磊，吴刚.吸入激素联合噻托溴铵治疗哮喘-慢阻肺重叠综合征的临床疗效评价[J].临床肺科杂志，2015，20(10)：1856-1860.
[8]	CHEN S， LI L， WU G. Evaluation of clinical effect by inhaled corticosteroid combined with tiotropium bromide in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome[J]. J Clin Pulmon Med， 2015， 20(10):1856-1860.
[9]	徐喜媛，杨敬平，宋慧芳.布地奈德/福莫特罗联合治疗对中重度的COPD患者细胞因子、肺功能及生活质量的影响[J].中国哮喘杂志（电子版），2013，7(5):341-344.
[10]	XU XY， YANG JP， SONG HF. Effect of combination treatment with budesonide and Salmeterol inhalation on cytokines， lung function and quality of life in patients with COPD[J]. Chin J Asthma (Electronic Edition)， 2013， 7(5):341-344.
[11]	中华医学会呼吸病学分会哮喘学组支气管哮喘防治指南[S].中华内科杂志，2003，4（12）：616.
[12]	Asthma Section of the Chinese Medical Association， Guidelines for the Prevention and Treatment of Bronchial Asthma[S]. Chin J Intern Med， 2003， 4(12):616.
[13]	朱文锋，王永炎，唐由之，等.中医临床诊疗术语[M].北京：中国标准出版社，2004：38.
[14]	〖JP2〗ZHU WF， WANG YY， TANG YZ， et al. Clinical Diagnosis and Treatment Term[M]. Beijing: Standards press of China， 2004:38.〖JP〗
[15]	孙永昌.哮喘-慢性阻塞性肺疾病重叠综合征[J].中华哮喘杂志(电子版)，2012，6(5):306-308.
[16]	〖JP3〗SUN YC. Asthma-chronic obstructive pulmonary disease overlap syndrome[J]. Chin J Asthma (Electronic Edition)， 2012， 6(5):306-308.〖JP〗
[17]	徐飞，董竞成.哮喘-慢性阻塞性肺疾病重叠综合征的临床研究进展[J].中国全科医学，2016，35(5):500-506.
[18]	XU F， DONG JC. Clinical research progress of asthma-COPD overlap syndrome[J]. Chin Gen Prac， 2016， 35(5):500-506.